My ePortfolio Register   

Genomic profiling of muscle invasive bladder cancer to predict response to bladder-sparing trimodality therapy

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.02.18
Views: 890
Rating:

Dr David Miyamoto - Massachusetts General Hospital, Boston, USA

Dr Miyamoto speaks with ecancer at the 2018 ASCO Genitourinary Cancers Symposium about genomic profiling of muscle invasive bladder cancer to predict response to bladder-sparing trimodality therapy.

He goes on to highlight that transcriptional profiling of muscle invasive bladder cancer revealed gene signatures correlated with response to chemoradiation, suggesting the potential of genomics to guide use of trimodality therapy.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence